BioNTech Shuts the Door on Tübingen and Turns Its Full Attention to Madrid

BioNTech is discovering that the road from pandemic-era vaccine maker to full-fledged oncology developer is paved with awkward choices. The Mainz-based company has just walked away from a bid of up to EUR 20 million for its Tübingen production site, and it is simultaneously absorbing the first major clinical disappointment of its cancer campaign. Both developments land less than two weeks before the data drop that will shape how investors judge the entire pipeline.

The stock is nursing a 25% gap to its 52-week high of EUR 105.80. In pre-market trading the shares changed hands at EUR 79.45, a shade below the previous close of EUR 79.55 — a decline of 0.1%. The broader picture is one of caution: the equity has given up a quarter of its peak value, and the market is plainly waiting for proof rather than promises.

A Consortium Walks Away, and the Shutdown Stands

The Tübingen decision is the clearest signal yet that management intends to shrink its way into shape. A group of investors led by Peter Löw had offered as much as EUR 20 million for the site, according to a Handelsblatt report. The proposal, first flagged by SWR citing Handelsblatt information, would have kept roughly 500 employees in work. Talks collapsed, and the closure stands.

Read through a commercial lens, the refusal is a statement of priorities. BioNTech passed up a short-term cash injection to avoid propping up capacity left over from the pandemic years. Capital and manpower are to be concentrated where future value is actually created — in oncology research and development. It is a rational call on paper, however painful for the workforce affected.

The retreat from German manufacturing has not gone unnoticed politically. Thomas Spies, the mayor of Marburg, wrote to Chancellor Friedrich Merz and the relevant ministers warning that the planned closure of the BioNTech plant in Marburg would undermine supply security. The restructuring reflects a shift to new production requirements, but it is generating friction on both the operational and the political front in the near term.

BNT113 Delivers the First Blow to the Cancer Story

The clinical setback came in AHEAD-MERIT, a Phase 2/3 trial testing BNT113 in combination with pembrolizumab in HPV16-positive head and neck cancer. At an interim analysis, the combination failed to beat pembrolizumab alone on the primary endpoint of progression-free survival.

The study is continuing in order to assess overall survival, which remains the one endpoint still in play. That keeps a narrow door open. Even so, missing the first target carries weight, and the question now is whether this is an isolated stumble or a sign of structural obstacles across the immunotherapy candidates.

Analysts have adjusted without capitulating. On 14 October, Canaccord Genuity trimmed its price target to $132 from $136 while keeping a Buy rating. Days earlier, Argus had initiated coverage with a Hold. The message from both houses is consistent: the market wants hard evidence before it re-rates the stock.

Madrid Becomes the Scorecard

The next concrete milestone is close at hand. From 23 to 27 October, the European Society for Medical Oncology holds its congress in Madrid, and BioNTech will bring 16 oncology abstracts to the podium.

Two readouts matter most. First, the global Phase 2 results from the ROSETTA Lung-107 study of the bispecific antibody Pumitamig combined with docetaxel in metastatic non-small cell lung cancer. Second, Phase 2 data on Pumitamig paired with the antibody-drug conjugate Elfetabart Drozuntecan in advanced solid tumours. Convincing response rates and a manageable tolerability profile would go a long way toward repairing the confidence dented by AHEAD-MERIT.

There is also the possibility that the ongoing overall survival analysis in AHEAD-MERIT delivers a statistically significant result for BNT113 under the trial's defined design. Such an outcome would demonstrate that the company's combination therapies can hold up even in difficult indications.

What Could Still Go Wrong

The opposite scenario is just as plausible. Should the final overall survival readout show no statistical advantage over monotherapy, BNT113 would be largely written off in this indication. Each further late-stage failure would not only weaken future revenue prospects but also force management into time-consuming reworking of the research portfolio.

Set against that risk is the breadth of what remains. A positive case rests on the depth of the pipeline and on disciplined use of capital. If the Madrid data support expectations, room for a gradual recovery in the share price stays open. If weak Phase 2 results undermine faith in the new drug combinations, investor reticence is likely to harden and valuation pressure to persist.

For holders, the coming fortnight is the test. BioNTech has shown it will cut capacity without sentiment. Now its laboratory output has to justify the sacrifices.